Deutsche Bank
ELTX icon

Deutsche Bank’s Elicio Therapeutics ELTX Stock Holding History

Deutsche Bank’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,349
Closed -$29K – 4175
2022
Q1 		$29K Sell
1,349
-140
-9% -$3.16K ﹤0.01% 3983
2021
Q4 		$43K Buy
1,489
+75
+5% +$3.79K ﹤0.01% 3998
2021
Q3 		$138K Buy
1,414
+1,059
+298% +$114K ﹤0.01% 3750
2021
Q2 		$46K Sell
355
-11
-3% -$1.59K ﹤0.01% 4323
2021
Q1 		$66K Buy
+366
New +$70.6K ﹤0.01% 4163

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Deutsche Bank's ELTX Position: Q2 2022 in Review

Deutsche Bank sold out of Elicio Therapeutics (ELTX) in Q2 2022, closing a stake of 1,349 shares — an estimated $29K sold.

Deutsche Bank first reported a position in ELTX in Q1 2021 and held it in 5 quarters. The position peaked at $138K in Q3 2021. 43 funds tracked by Wall St. Rank hold ELTX as of Q2 2022.

  • Deutsche Bank reported no remaining Elicio Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Deutsche Bank sold 1,349 Elicio Therapeutics shares in Q2 2022, an estimated $29K.
  • Deutsche Bank first reported a position in Elicio Therapeutics in Q1 2021 and held it in 5 quarters.
  • Deutsche Bank's Elicio Therapeutics position peaked at $138K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2022.

Based on Deutsche Bank's 13F filing for Q2 2022, filed 11 Aug 2022.